|
|
|
|
Positive status with respect to anti-JC virus antibodies, prior use to immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct levels of PML risk in natalizumab-treated patients with multiple sclerosis. |
|